AstraZeneca and Bristol-Myers Squibb Statement on Proposal by the American Diabetes Association for Independent Review of

  AstraZeneca and Bristol-Myers Squibb Statement on Proposal by the American
  Diabetes Association for Independent Review of Incretin-Based Therapies

Business Wire

PRINCETON, N.J. & WILMINGTON, Del. -- June 12, 2013

Earlier this week, the American Diabetes Association called for manufacturers
of incretin-based therapies to make patient-level data available from clinical
trials for an independent analysis of pancreatic safety. AstraZeneca (NYSE:
AZN) and Bristol-Myers Squibb Company (NYSE: BMY) are pleased to see the
American Diabetes Association’s engagement and efforts to facilitate further
understanding of this topic.

AstraZeneca and Bristol-Myers Squibb have been and will continue to work with
health authorities and scientific experts around the world to closely monitor
the use of our GLP-1 receptor agonist and DPP-4 inhibitor through
comprehensive surveillance programs to ensure patients and physicians have a
clear understanding of the risk/benefit profile of these medications.

AstraZeneca and Bristol-Myers Squibb recognize there can be value in pooling
patient level data from trials of agents in a class for the purpose of an
independent meta-analysis of safety sponsored by the American Diabetes
Association. We support the American Diabetes Association’s initiative to make
scientifically valid results of a pooled analysis of safety data available to
the public and scientific communities through an independent review, and look
forward to a discussion with the American Diabetes Association about the
logistics of its proposal.

AstraZeneca and Bristol-Myers Squibb have an unwavering commitment to patient
safety and the appropriate use of our medicines. We are committed to
communicating accurate and meaningful information about our sponsored clinical
trials in a timely, accurate, balanced and complete manner, regardless of
outcome and with respect for patient confidentiality.

AstraZeneca/Bristol-Myers Squibb Diabetes Alliance

Dedicated to addressing the global burden of diabetes by advancing
individualized patient care, AstraZeneca and Bristol-Myers Squibb are working
in collaboration to research, develop and commercialize a versatile portfolio
of innovative treatment options for diabetes and related metabolic disorders
that aim to provide treatment effects beyond glucose control. Find out more
about the Alliance and our commitment to meeting the needs of health care
professionals and people with diabetes at www.astrazeneca.com or www.bms.com.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialization of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to
discover, develop and deliver innovative medicines that help patients prevail
over serious diseases. For more information about Bristol-Myers Squibb, visit
www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

Contact:

Media:
Bristol-Myers Squibb
Ken Dominski, 609-252-5251
ken.dominski@bms.com
or
AstraZeneca
Kirsten Evraire, 302-885-0435
kirsten.evraire@astrazeneca.com
or
Investors:
Bristol-Myers Squibb
John Elicker, 609-252-4611
john.elicker@bms.com
or
AstraZeneca
Karl Hard, 44-20-7604-8123
karl.j.hard@astrazeneca.com